Nature Medicine | Spoonful of Medicine
What’s in the mix for TB? The drugome suggests new cocktail solutions
By Stu Hutson The first-line regime of tuberculosis drugs has remained virtually unchanged for a half century. But instead of improving on these medications, some researchers say it’s time to scour the lists of already-approved drugs for other indications or start from scratch to curb the more than 1.7 million deaths from tuberculosis (TB) each year. In early November, for example, the New York–based TB Alliance announced the launch of a clinical trial to test a radically different drug cocktail. “We see this as a paradigm shift in methodology,” says Ann Ginsberg, the organization’s chief medical officer, “And it’s been
Recent comments
Real-time tissue analysis could guide brain tumor surgery
Bundled RNA balls silence brain cancer gene expression
Ebola outbreak in West Africa lends urgency to recently-funded research